Indivior Pharmaceuticals announces special shareholder meeting on merger with Supernus
INDV•Indivior Pharmaceuticals will hold a special stockholder meeting on Oct. 15, 2026, for investors to vote on its proposed merger with Supernus. Supernus would be the surviving company, Indivior would become its wholly owned subsidiary, and the company would be renamed Supernus, Inc.
1. Merger vote scheduled
Indivior Pharmaceuticals will hold a special stockholder meeting on Oct. 15, 2026, in connection with its proposed merger with Supernus. Investors are set to vote on the transaction.
2. Proposed company structure
If completed, Supernus would be the surviving company, Indivior would become a wholly owned subsidiary, and Indivior would be renamed Supernus, Inc.
